Dinutuximab beta effectively treats Ewing sarcoma when combined with chemotherapy
Roberta Frapolli1, Marina Meroni1, Ezia Bello1
1Laboratory of Cancer Pharmacology, Department of Experimental Oncology, Instituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Abstract:
Ewing sarcoma is a rare and aggressive cancer of the bone and soft tissues primarily affecting children and young adults. Prognosis for patients with metastatic or recurrent disease remains poor despite intensive multimodal therapy, highlighting the need of novel therapeutic approaches. The disialoganglioside GD2 is highly expressed on Ewing sarcoma cells, making this tumor eligible for anti-GD2 immunotherapy with dinutuximab beta. Through in vitro and in vivo approaches, this study demonstrated that dinutuximab beta effectively suppressed tumor growth by 60% (p = 0.0135) and improved survival rate by 68% (p = 0.0006) in a mouse model xenograft. The combination therapy with doxorubicin demonstrated superior efficacy compared to monotherapy, with enhanced tumor suppression (86%; p = 0.0009) and an extension of survival rate (146%; p = 0.000025). This study showed that dinutuximab beta, particularly in combination with standard chemotherapy, offers a promising approach to improve outcomes for high-risk Ewing sarcoma patients, providing a more effective alternative to current treatments.
Insights
Dinutuximab beta immunotherapy shows promise for Ewing sarcoma. Combining it with doxorubicin significantly improved tumor suppression and survival rates in preclinical models, offering a potential new treatment for high-risk patients.
Area of Science:
- Oncology
- Immunotherapy
- Pediatric Cancers
Background:
- Ewing sarcoma is an aggressive bone and soft tissue cancer with poor prognosis in advanced stages.
- Current treatments lack efficacy for metastatic or recurrent disease, necessitating novel therapeutic strategies.
- Disialoganglioside GD2 is a tumor antigen highly expressed on Ewing sarcoma cells, making it a target for immunotherapy.
Purpose of the Study:
- To evaluate the efficacy of dinutuximab beta, an anti-GD2 immunotherapy, in treating Ewing sarcoma.
- To investigate the synergistic effect of combining dinutuximab beta with doxorubicin chemotherapy.
Main Methods:
- In vitro and in vivo studies were conducted using a mouse xenograft model of Ewing sarcoma.
- Tumor growth suppression and survival rates were measured for monotherapy and combination therapy groups.
Main Results:
- Dinutuximab beta monotherapy suppressed tumor growth by 60% (p=0.0135) and improved survival by 68% (p=0.0006).
- Combination therapy with doxorubicin demonstrated superior efficacy, achieving 86% tumor suppression (p=0.0009) and a 146% increase in survival (p=0.000025).
Conclusions:
- Dinutuximab beta is an effective agent against Ewing sarcoma.
- Combination therapy with dinutuximab beta and doxorubicin offers a significantly improved therapeutic strategy for high-risk Ewing sarcoma patients.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...